ACRX Share Price

Open 2.70 Change Price %
High 2.75 1 Day -0.05 -1.85
Low 2.65 1 Week -0.20 -7.02
Close 2.65 1 Month -0.10 -3.64
Volume 166956 1 Year -0.33 -11.07
52 Week High 4.50
52 Week Low 2.40
ACRX Important Levels
Resistance 2 2.74
Resistance 1 2.70
Pivot 2.68
Support 1 2.60
Support 2 2.56
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

ACRX Technical Analysis 5
As on 20th Jan 2017 ACRX Share Price closed @ 2.65 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.24 & Strong Sell for SHORT-TERM with Stoploss of 2.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACRX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ACRX Other Details
Segment EQ
Market Capital 65612500.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.acelrx.com
ACRX Address
ACRX
351 Galveston Drive
Redwood City, CA 94063
United States
Phone: 650-216-3500
Fax: 650-216-6500
Interactive Technical Analysis Chart AcelRx Pharmaceuticals, Inc. ( ACRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AcelRx Pharmaceuticals, Inc.
ACRX Business Profile
AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company has completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02, for the treatment of cancer breakthrough pain (BTP), and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. The Company is preparing to initiate two Phase 3 clinical trials for its product candidate, the Sufentanil NanoTab PCA System, or ARX-01. Its operations are based in Redwood City, California.